Serum level of dipeptidyl peptidase-4 as a potential biomarker for medullary thyroid cancer
Keywords:
body-mass index, dipeptidyl peptidase 4, insulin resistance, medullary thyroid cancer, metabolic syndromeAbstract
Summary. Aim: Adipokines are the proteins secreted from adipose tissue and play an important role in the control of metabolism. Dipeptidyl peptidase-4 (DPP4) is a novel adipokine with different biological role. As indicated by various studies, serum levels of DPP4 had been associated with body mass index (BMI), insulin resistance, metabolic syndrome and malignancy. The aim of this study was to assess the serum levels of DPP4 in patients with medullary thyroid cancer (MTC) in comparison with these in the control group. Materials and Methods: This study was performed on 45 MTC patients (24 females and 21 males) and 45 healthy controls (21 females and 24 males). DPP4 and insulin serum levels were measured by ELISA, fasting glucose serum levels by enzyme-calorimetric method and insulin resistance index (HOMA-IR) by calculation using relevant equation. BMI (kg/m2) was also calculated. Results: Our data did not demonstrate a significant difference between serum DPP4 levels in MTC and healthy group (41.06 ± 22.08 ng/ml vs 39.94 ± 20.77 ng/ml, p > 0.05). Additionally, no significant difference was found in serum insulin and HOMA-IR concentrations between MTC patients and the controls (p > 0.05). Conclusions: This study suggests that the fluctuation in the levels of DPP4 does not play an important role in prognosis, early detection and diagnosis of MTC. Furthermore, higher levels of DPP4 cannot be considered as a risk factor for MTC.
References
Abooshahab R, Yaghmaei P, Ghadaksaz HG, et al. Lack of association between serum Adiponectin/Leptin levels and medullary thyroid cancer. Asian Pac J Cancer Prev 2016; 17: 3861–4.
Hedayati M, Yeganeh M, Sheikholeslami S, et al. Wide screening of RET proto-oncogene in Iranian medullary thyroid carcinoma patients: 13 years study. Endocrine Abstracts. 2015.
Hedayati M, Zarif Yeganeh M, Sheikhol Eslamis, et al. Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res 2011; (2011): 1–6.
Griebeler M, Gharib H, Thompson G. Medullary thyroid carcinoma. Endocrine Practice 2013; 19: 703–11.
Rendl G, Manzl M, Hitzl W, et al. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol 2008; 69: 497–505.
Polyzos S, Anastasilakis A. Alterations in Serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review. Thyroid 2010; 20: 265–71.
Polyzos S, Anastasilakis A. Clinical complications following thyroid fine-needle biopsy: a systematic review. Clin Endocrinol 2009; 71: 157–65.
Nien F, Chang T. Biomarkers of medullary thyroid cancer in the prediction of cure after thyroidectomy. J Formosan Med Associat 2015; 114: 793–4.
Gorrell M. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Science 2005; 108: 277–92.
Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proceed NAS 2003; 100: 5063–8.
Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917–25.
Yu D, Yao T, Chowdhury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010; 277: 1126–44.
Gorrell M, Gysbers V, McCaughan G. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scandinav J Immunol 2001; 54: 249–64.
Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond Its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999; 274: 3988–93.
Arrebola Y, Gómez H, Valiente P, et al. Dipeptidyl peptidase IV and its implication in cancer. Biotecnol Aplicada 2014; 31: 102–10.
Havre P. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008; 13: 1634.
Wesley U, Albino A, Tiwari S, et al. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999; 190: 311–22.
Asada Y, Aratake Y, Kotani T, et al. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathology 1993; 23: 265–70.
Šedo A, Křepela E, Kasafírek E. Dipeptidyl peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumours and lung parenchyma. J Cancer Res Clin Oncol 1991; 117: 249–53.
Kikkawa F, Kajiyama H, Ino K, et al. Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer 2003; 105: 779–83.
Bogenrieder T, Finstad C, Freeman R, et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997; 33: 225–32.
Fröhlich E, Maier E, Wahl R. Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies. J Exp Clin Cancer Res 2012; 31: 45.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA. Cancer J Clinicians 2012; 62: 10–29.
Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Hormone Mol Biol Clin Investig 2015; 21: 57–74.
Aertgeerts A. N-linked glycosylation of dipeptidyl peptidase IV (CD26): Effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci 2004; 13: 145–54.
Iwaki-Egawa A, Watanabe A, Kikuya Y, Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem 1998; 124: 428–33.
Yazbeck R, Howarth G, Abbott C. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009; 30: 600–7.
Qi S, Riviere P, Trojnar J, et al. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. J Biochem 2003; 373: 179–89.
Yamabe T, Takakura K, Sugie K, et al. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology 1997; 91: 151–8.
DuBois R. Leukotriene A4 signaling, inflammation, and cancer. JNCI J Nat Cancer Inst 2003; 95: 1028–9.
Kikkawa F, Kajiyama H, Shibata K, et al. Dipeptidyl peptidase IV in tumor progression, Biochimica Et Biophysica Acta (BBA). Proteins Proteom 2005; 1751: 45–51.
Tanaka T, Umeki K, Yamamoto I, et al. CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Int J Cancer 1995; 64: 326–31.
Maruta J, Hashimoto H, Yamashita H, et al. Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma. Arch Surg 2004; 139: 83–8.
Larrinaga G, Blanco L, Errarte P, et al. Altered peptidase activities in thyroid neoplasia and hyperplasia. Disease Markers 2013; 35: 825–32.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
